Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis.

@article{Khan1997EliminationAB,
  title={Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis.},
  author={Shoukat Alim Khan and J. A. Kanis and Sam D. Vasikaran and Walter F Kline and Bogdan K. Matuszewski and Eugene V. McCloskey and M. N. C. Beneton and Barry J. Gertz and David G Sciberras and Sherry D. Holland and Jane M. Orgee and Geoffrey Coombes and Shirley R Rogers and Arturo G Porras},
  journal={Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research},
  year={1997},
  volume={12 10},
  pages={1700-7}
}
Postmenopausal women with established vertebral osteoporosis were studied for 2 years to determine the terminal elimination half-life and the duration of response to treatment with intravenous alendronate (30 mg) given over 4 days. The urinary excretion of alendronate followed a multiexponential decline. Approximately 50% of the total dose was excreted over the first 5 days, and a further 17% was excreted in the succeeding 6 months. Thereafter, there was a much slower elimination phase with an… CONTINUE READING